Stock Analysis

# Calculating The Fair Value Of EZZ Life Science Holdings Limited (ASX:EZZ)

Published

Today we will run through one way of estimating the intrinsic value of EZZ Life Science Holdings Limited (ASX:EZZ) by projecting its future cash flows and then discounting them to today's value. We will use the Discounted Cash Flow (DCF) model on this occasion. Models like these may appear beyond the comprehension of a lay person, but they're fairly easy to follow.

We generally believe that a company's value is the present value of all of the cash it will generate in the future. However, a DCF is just one valuation metric among many, and it is not without flaws. If you want to learn more about discounted cash flow, the rationale behind this calculation can be read in detail in the Simply Wall St analysis model.

View our latest analysis for EZZ Life Science Holdings

## What's The Estimated Valuation?

We are going to use a two-stage DCF model, which, as the name states, takes into account two stages of growth. The first stage is generally a higher growth period which levels off heading towards the terminal value, captured in the second 'steady growth' period. To start off with, we need to estimate the next ten years of cash flows. Seeing as no analyst estimates of free cash flow are available to us, we have extrapolate the previous free cash flow (FCF) from the company's last reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.

Generally we assume that a dollar today is more valuable than a dollar in the future, so we need to discount the sum of these future cash flows to arrive at a present value estimate:

#### 10-year free cash flow (FCF) forecast

 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 Levered FCF (A\$, Millions) AU\$1.46m AU\$1.25m AU\$1.13m AU\$1.06m AU\$1.01m AU\$993.5k AU\$984.4k AU\$983.6k AU\$988.6k AU\$997.6k Growth Rate Estimate Source Est @ -21.8% Est @ -14.7% Est @ -9.73% Est @ -6.25% Est @ -3.81% Est @ -2.11% Est @ -0.91% Est @ -0.08% Est @ 0.51% Est @ 0.91% Present Value (A\$, Millions) Discounted @ 6.6% AU\$1.4 AU\$1.1 AU\$0.9 AU\$0.8 AU\$0.7 AU\$0.7 AU\$0.6 AU\$0.6 AU\$0.6 AU\$0.5

("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = AU\$7.0m

After calculating the present value of future cash flows in the initial 10-year period, we need to calculate the Terminal Value, which accounts for all future cash flows beyond the first stage. The Gordon Growth formula is used to calculate Terminal Value at a future annual growth rate equal to the 5-year average of the 10-year government bond yield of 1.9%. We discount the terminal cash flows to today's value at a cost of equity of 6.6%.

Terminal Value (TV)= FCF2032 × (1 + g) ÷ (r – g) = AU\$998k× (1 + 1.9%) ÷ (6.6%– 1.9%) = AU\$22m

Present Value of Terminal Value (PVTV)= TV / (1 + r)10= AU\$22m÷ ( 1 + 6.6%)10= AU\$11m

The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is AU\$18m. To get the intrinsic value per share, we divide this by the total number of shares outstanding. Compared to the current share price of AU\$0.3, the company appears about fair value at a 19% discount to where the stock price trades currently. Valuations are imprecise instruments though, rather like a telescope - move a few degrees and end up in a different galaxy. Do keep this in mind.

## The Assumptions

The calculation above is very dependent on two assumptions. The first is the discount rate and the other is the cash flows. Part of investing is coming up with your own evaluation of a company's future performance, so try the calculation yourself and check your own assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at EZZ Life Science Holdings as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 6.6%, which is based on a levered beta of 0.915. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.

## Next Steps:

Whilst important, the DCF calculation is only one of many factors that you need to assess for a company. It's not possible to obtain a foolproof valuation with a DCF model. Preferably you'd apply different cases and assumptions and see how they would impact the company's valuation. If a company grows at a different rate, or if its cost of equity or risk free rate changes sharply, the output can look very different. For EZZ Life Science Holdings, we've put together three further aspects you should consider:

1. Risks: You should be aware of the 2 warning signs for EZZ Life Science Holdings (1 is concerning!) we've uncovered before considering an investment in the company.
2. Future Earnings: How does EZZ's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
3. Other High Quality Alternatives: Do you like a good all-rounder? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing!

PS. The Simply Wall St app conducts a discounted cash flow valuation for every stock on the ASX every day. If you want to find the calculation for other stocks just search here.

### Valuation is complex, but we're helping make it simple.

Find out whether EZZ Life Science Holdings is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis